Arylalkyl-thiadiazinones

Details Arylalkyl-thiadiazinones Arylalkyl-thiadiazinones

1998-01-20

2000-02-15

Shah, Mukund J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

544 8, A61K 3154

Patent

active

060253541

ABSTRACT:
Arylalkyl-thiadiazinone derivatives of the formula I ##STR1## and physiologically unobjectionable salts thereof in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and Q have the meanings given in claim 1, exhibit phosphodiesterase IV inhibition and can be used for the therapy of asthmatic disorders.

REFERENCES:
patent: 4916128 (1990-04-01), Jonas et al.
patent: 5276027 (1994-01-01), Jonas et al.
patent: 5434149 (1995-07-01), Jonas et al.
patent: 5859008 (1999-01-01), Jonas et al.
Bauditz et al. "Treatment with Tumour Necrosis Factor Inhibitor Oxpentifylline does not Improve Corticosteroid Dependent Chronic Active Crohn's Disease," Gut, vol. 40, No. 4, pp. 470-474, Apr. 1997.
Nicholson et al., "Differential Modulation of Tissue Function and Therapeutic Potential of Selective Inhibitors of Cyclic Nucleotide Phosphodiesterase Isoenzymes," TIPS, vol. 12, pp. 19-27, Jan. 1991.
Sommer et al., "The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis," Nature Medicine, vol. 1, No. 3, pp. 244-248, Mar. 1995.
Eigler et al., "Taming TNF: strategies to restrain this proinflammatory cytokine," Immunology Today, vol. 18, No. 10, pp. 487-492, Oct. 1997.

Affiliated with

Also associated with

Rating

Arylalkyl-thiadiazinones does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Arylalkyl-thiadiazinones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylalkyl-thiadiazinones will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1906095